Hyaluronidase enzyme formulations for high volume administration
In one aspect, the present disclosure provides a formulation comprising a hyaluronidase enzyme and a therapeutically effective amount of an active ingredient. In another aspect, the present disclosure provides a method of administering a high volume of the formulation in a single administration to treat a disease or disorder in a subject.
1 . A method of subcutaneous administration of a hyaluronidase PH20 enzyme formulation to a subject in need thereof,
the method comprising subcutaneously administering to the subject about 3 mL to about 50 mL of a formulation comprising recombinant human hyaluronidase PH20 enzyme comprising a sequence having at least 95% amino acid sequence identity to an amino acid sequence selected from any of SEQ ID NO: 1 through 7, and having an activity of about 500 U/mL to about 5,000 U/mL,
wherein the subcutaneous administration occurs via a high volume autoinjector at a rate of about 0.10 mL/sec to about 1.0 mL/sec.
2 . The method of claim 1 , wherein the formulation further comprises an active ingredient selected from a small molecule antiviral, a peptide, a nanoparticle, an antibody, and an antibody fragment.
3 . The method of claim 2 , wherein the active ingredient is an antibody.
4 . The method of claim 2 , wherein the active ingredient is an antibody fragment.
5 . The method of claim 2 , wherein the active ingredient is a small molecule antiviral.
6 . The method of claim 2 , wherein the active ingredient is a peptide.
7 . The method of claim 1 , wherein the subcutaneous administration occurs via the high volume autoinjector with a starting delivery force of about 3 lbf to about 50 lbf.
8 . The method of claim 1 , wherein the subcutaneous administration occurs via the high volume autoinjector with an ending delivery force of about 5 lbf to about 20 lbf.
9 . The method of claim 1 , wherein the subcutaneous administration occurs via the high volume autoinjector using a compressed-gas cylinder as an energy source.
10 . The method of claim 1 , wherein the subcutaneous administration occurs via the high volume autoinjector with a starting pressure of about 50 psi to about 200 psi.
11 . The method of claim 1 , wherein the subcutaneous administration occurs via the high volume autoinjector with an ending pressure of about 20 psi to about 75 psi.
12 . A method of reducing one or more side effects of a high-volume subcutaneous injection in a subject in need thereof,
the method comprising subcutaneously administering to the subject about 3 mL to about 50 mL of a formulation comprising recombinant human hyaluronidase PH20 enzyme comprising a sequence having at least 95% amino acid sequence identity to an amino acid sequence selected from any of SEQ ID NO: 1 through 7, and having an activity of about 500 U/mL to about 5,000 U/mL, and an active ingredient selected from a small molecule, a peptide, a nanoparticle an antibody, an antibody fragment, and a small molecule antiviral,
wherein the subcutaneous administration occurs via a high volume autoinjector at a rate of about 0.10 mL/sec to about 1.0 mL/sec and the one or more side effects are selected from pain and discomfort at the injection site, back leakage at the injection site, swelling volume at the injection site, swelling height at the injection site, bleb swelling size, bleb induration, and bleb resolution time.
13 . The method of claim 12 , wherein the active ingredient is an antibody.
14 . The method of claim 12 , wherein the active ingredient is an antibody fragment.
15 . The method of claim 12 , wherein the active ingredient is a small molecule antiviral.
16 . The method of claim 12 , wherein the active ingredient is a peptide.
17 . The method of claim 12 , wherein the subcutaneous administration occurs via the high volume autoinjector with a starting delivery force of about 3 lbf to about 50 lbf and with an ending delivery force of about 5 lbf to about 20 lbf.
18 . The method of claim 12 , wherein the subcutaneous administration occurs via the high volume autoinjector using a compressed-gas cylinder as an energy source.
19 . The method of claim 12 , wherein the subcutaneous administration occurs via the high volume autoinjector with a starting pressure of about 50 psi to about 200 psi and with an ending pressure of about 20 psi to about 75 psi.
20 . The method of claim 12 , wherein the one or more side effects are reduced compared to the one or more side effects from a high-volume subcutaneous injection of a similar formulation that does not comprise the recombinant human hyaluronidase PH20 enzyme.